Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Pevifoscorvir with Itraconazole and Carbamazepine in Healthy Volunteers
NCT06672900Phase 1Active, not recruiting
- Sponsor
- Aligos Therapeutics
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pevifoscorvir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Aligos Therapeutics. Primary endpoints: Area under the concentration time curve at 29 days, Time to maximum plasma concentration at 29 days and 4 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
pevifoscorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06672900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672900.